Show an ad over header. AMP

The world is watching the FDA's AstraZeneca decision

AstraZeneca's coronavirus vaccine took yet another public relations hit yesterday, when the European Medicines Agency announced that the shot is linked to blood clots, and they should be listed as a "very rare" side effect of the vaccine.

What we're watching: Even before the link was announced, the U.S. didn't need the AstraZeneca vaccine, based on its existing supply of other shots. But what the Food and Drug Administration decides to do about the vaccine — if the company seeks U.S. authorization — will likely have global ramifications.


Driving the news: The EMA said the benefits of the vaccine still outweigh its risk, STAT reports. “This vaccine has proven to be highly effective to prevent severe disease and hospitalization,” said Emer Cooke, the EMA’s executive director. “And it is saving lives.”

  • The U.K., however, recommended that people under 30 receive other vaccines, and other European countries have already restricted use of the vaccine to older populations.

Why it matters: The AstraZeneca vaccine has already been plagued by a series of self-imposed mishaps throughout its rollout. Even if blood clots are an exceedingly rare side effect — which experts stress they are — there's risk of further damage to the shot's reputation.

  • "Very serious and very rare side-effects do occur, with essentially every medical intervention ever developed (not just vaccines)," said John Moore, a professor of microbiology and immunology at Cornell.
  • "But with the spotlight on Covid-19 vaccines, the public is going to hear 'very serious' and tune out 'very rare.' So, there are going to be major perceptional and confidence problems moving forward."

The big picture: The shot is relatively cheap and easy to make, and is the main shot being used by the COVAX initiative. It's particularly important for developing countries.

  • The U.S., on the other hand, doesn't need the vaccine; it has already purchased more than enough doses of other vaccines to cover its entire population.

Yes, but: What U.S. regulators say about the shot could still have global consequences, especially given its chaotic rollout.

  • "Confidence in the AZ vaccine, which will be informed by the U.S. FDA position, will be critically important for global vaccine efforts," said Krishna Udayakumar, director of the Duke Global Health Innovation Center.
  • "The U.S. FDA position will likely also impact what happens to the current and future U.S. supply of the AZ vaccine – even if we don’t use them, it would be helpful for the vaccine to have FDA EUA for the U.S. to confidently provide doses, via donations or loans, to other countries," he added.

What we're watching: The company hasn't yet submitted an application for emergency use authorization to the FDA, but it could do so in the coming weeks.

  • If the company does seek FDA authorization, "I think it's unlikely they won't approve it, because despite this rare side effect, it’s a good vaccine," said Nahid Bhadelia, medical director of Special Pathogens Unit at Boston Medical Center.
  • But even if it still authorizes the shot, it could put age parameters on eligibility.
  • "The [problem] is even if authorized, the U.S. is probably going to be giving away the doses to other countries anyway, which makes the confidence impact more limited," said former FDA Commissioner Mark McClellan.

The bottom line: Finding alternatives to the AstraZeneca shot is "a real problem," Moore said.

  • "The one advantage of the AstraZeneca vaccine was its low cost/high production characteristics. Perhaps [Johnson & Johnson] and Novavax can fill some of the gaps that may arise," he wrote in an email, adding that the Pfizer and Moderna vaccines are "problematic for global roll-out."
  • "Otherwise, as of now, it’s the Russian and Chinese vaccines, and there remain real doubts about their safety, efficacy and production capacity for use on a global scale."

European soccer goes to war over wealthy clubs' plans for exclusive "Super League"

Europe's biggest soccer clubs have established The Super League, a new midweek tournament that would compete with — and threaten the very existence of — the Champions League.

Why it matters: This new league, set to start in 2023, "would bring about the most significant restructuring of elite European soccer since the 1950s, and could herald the largest transfer of wealth to a small set of teams in modern sports history," writes NYT's Tariq Panja.

Keep reading... Show less

81% of S&P 500 companies have reported a positive earnings surprise for Q1

First-quarter earnings so far have been very strong, outpacing even the rosy expectations from Wall Street and that's a trend that's expected to continue for all of 2021. S&P 500 companies are on pace for one of the best quarters of positive earnings surprises on record, according to FactSet.

Why it matters: The results show that not only has the earnings recession ended for U.S. companies, but firms are performing better than expected and the economy may be justifying all the hype.

Keep reading... Show less

NASA's Mars helicopter takes flight as first aircraft piloted on another planet

NASA successfully piloted the Ingenuity Mars helicopter for its first experimental flight on Monday, briefly hopping the aircraft as NASA's Perseverance rover collected data.

Why it matters: Ingenuity's short flight marks the first time a human-built aircraft has flown on a world other than Earth, opening the door to new means of exploring planets far from our own.

Keep reading... Show less

All U.S. adults now eligible for COVID-19 vaccine, meeting Biden's April 19 deadline

All 50 U.S. states, plus Washington, D.C. and Puerto Rico, have now made U.S. adults over the age of 16 eligible for COVID-19 vaccines, meeting President Biden's April 19 deadline.

Why it matters: The landmark speaks to the increased pace of the national vaccination campaign, but will increase pressure on the federal government, states and pharmaceutical companies to provide adequate vaccine supply and logistics.

Keep reading... Show less

Minneapolis braces for a verdict in the Derek Chauvin trial

Minneapolis is waking up to images of an occupied city on Monday, as the city and the world await a verdict in the Derek Chauvin trial.

What it's like: Residents running errands, picking up dinner and heading to the dog park in recent days encountered heavily-armed National Guard troops stationed throughout the city.

Keep reading... Show less

Russian authorities say jailed opposition leader Navalny has been transferred to hospital

Russian opposition leader Alexei Navalny has been hospitalized, one day after his doctor warned that the jailed Putin critic "could die at any moment," Russia's prison service said Monday.

Why it matters: News that Navalny's condition had severely deteriorated on the third week of a hunger strike prompted outrage from his supporters and international demands for Russia to provide him with immediate medical treatment.

Keep reading... Show less

The state worst hit by the pandemic

Data: Hamilton Place Strategies; Chart: Will Chase/Axios

When the coronavirus pandemic hit, the job facing governments was to save lives and save jobs. Very few states did well on both measures, while New York, almost uniquely, did particularly badly on both.

Why it matters: The jury is still out on whether there was a trade-off between the dual imperatives; a new analysis from Hamilton Place Strategies shows no clear correlation between the two.

Keep reading... Show less

Biden confronts eroded credibility on climate action and Paris agreement

The biggest hurdle for President Biden in winning new emissions reduction commitments at this week's White House summit is America's on-again, off-again history of climate change efforts.

Why it matters: The global community is off course to meet the temperature targets contained in the Paris Climate Agreement. The White House wants the summit Thursday and Friday to begin to change that.

Keep reading... Show less

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories